Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;4(4):665-95.
doi: 10.3390/jcm4040665.

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Nestor R Ramos  1 , Clifton C Mo  2 , Judith E Karp  3 , Christopher S Hourigan  4
Affiliations

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Nestor R Ramos et al. J Clin Med. 2015 Apr.

Abstract

The limited sensitivity of the historical treatment response criteria for acute myeloid leukemia (AML) has resulted in a different paradigm for treatment compared with most other cancers presenting with widely disseminated disease. Initial cytotoxic induction chemotherapy is often able to reduce tumor burden to a level sufficient to meet the current criteria for "complete" remission. Nevertheless, most AML patients ultimately die from their disease, most commonly as clinically evident relapsed AML. Despite a variety of available salvage therapy options, prognosis in patients with relapsed or refractory AML is generally poor. In this review, we outline the commonly utilized salvage cytotoxic therapy interventions and then highlight novel investigational efforts currently in clinical trials using both pathway-targeted agents and immunotherapy based approaches. We conclude that there is no current standard of care for adult relapsed or refractory AML other than offering referral to an appropriate clinical trial.

Keywords: AML; leukemia; neoplasm metastasis; relapse; salvage therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment algorithm for patients with RR-AML in 2015. There is no standard of care for the treatment of relapsed or refractory AML. A clinical trial is always the preferred option. The above algorithm is based on current clinical practice and will hopefully change in coming years due to improvements. In particular the targeted and immunotherapeutic agents detailed in this review may ultimately have utility in (1) initial therapy; (2) as a bridge to, or as a temporizing measure before, allo-HSCT; and/or (3) as part of consolidative therapy. * Achievement of a complete remission (CR) prior to undergoing alloHSCT is associated with best survival and is generally preferred. The survival of patients with residual disease undergoing alloHSCT varies considerably however and this therapy may be a reasonable option in selected patients not in CR [125]. HMA: Hypomethylating agent. LDAC: Low-dose cytosine arabinoside. Allo-HSCT: Allogeneic Hematopoietic Stem Cell Transplant.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. American Cancer Society . Cancer Facts & Figures 2015. American Cancer Society; Atlanta, GA, USA: 2015. p. 4.
    1. Walter R.B., Othus M., Burnett A.K., Lowenberg B., Kantarjian H.M., Ossenkoppele G.J., Hills R.K., Ravandi F., Pabst T., Evans A., et al. Resistance prediction in aml: Analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOC and MD Anderson Cancer Center. Leukemia. 2014;29:312–320. doi: 10.1038/leu.2014.242. - DOI - PMC - PubMed
    1. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N. Engl. J. Med. 1999;341:1051–1062. doi: 10.1056/NEJM199909303411407. - DOI - PubMed
    1. Bergua J.M., Montesinos P., Martinez-Cuadrón D., Fernández-Abellán P., Serrano J., Sayas M.J., Prieto-Fernandez J., Garcia R., Garcia-Huerta A.J., Barrios M., et al. A prognostic index for patients with refractory or in first relapsed acute myeloid leukemia treated with FLAG-ida or FLAGO-ida. Blood. 2014;124:1049.
    1. Breems D.A., Van Putten W.L., Huijgens P.C., Ossenkoppele G.J., Verhoef G.E., Verdonck L.F., Vellenga E., De Greef G.E., Jacky E., Van der Lelie J., et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J. Clin. Oncol. 2005;23:1969–1978. doi: 10.1200/JCO.2005.06.027. - DOI - PubMed